Original text
Rate this translation
Your feedback will be used to help improve Google Translate
Home
Zydus Lifesciences Limited
Press Release Oct 25 2023
Business
Oct 25 2023
5 min read

Press Release Oct 25 2023

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 25, 2023, titled "Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".

View Attachment